RxDoctor Payments Data

Joanna Bloomer, APRN

Psychiatric/Mental Health · Greenup, KYNPI 1407197635

Payments from drug & device makers

$3,532in general payments, 2019–2025

Across 191 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$872
  • Otsuka America Pharmaceutical, Inc.$515
  • Johnson & Johnson$389
  • Alkermes, Inc.$382
  • Teva Pharmaceuticals USA, Inc.$343
  • Vanda Pharmaceuticals Inc.$288
  • plus $744 from 9 others

What the payments were for

  • Food & beverage$3,50599%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,532 in reported general payments places this provider in the 80th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$7,968
Medicare patients
29
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate46$103,695
VraylarCariprazine Hcl69$99,951
Abilify MaintenaAripiprazole27$77,007
RexultiBrexpiprazole27$55,565
Aripiprazole78$16,224
Atomoxetine Hcl20$3,059
Desvenlafaxine Succinate ErDesvenlafaxine Succinate50$2,161
Duloxetine Hcl30$1,617
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl17$1,465
Mirtazapine46$1,327
Paliperidone ErPaliperidone11$1,282
Divalproex Sodium25$1,277
Carbamazepine ErCarbamazepine13$1,071
Prazosin Hcl26$907
Buspirone Hcl72$844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$515$132,57254 claims
Johnson & JohnsonInvega Sustenna$389$103,69546 claims
AbbVieVraylar$872$99,95169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Greenup

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →